Data + Studies | Aerobiotix

Data + Studies

Multiple peer-reviewed studies support the effectiveness of Aerobiotix technology.

Aerobiotix, Inc. continually commissions independent and collaborative research on our technologies, partnering with leading biomedical institutions globally. These studies range from laboratory testing, case studies, conference presentations and peer-reviewed papers.

 

 

Research

CORRELATION OF THE AIR–SURFACE NEXUS OF BACTERIAL BURDEN DURING ROUTINE PATIENT CARE

Bischoff, W., MD, Russell, G. MS. Infection Control & Hospital Epidemiology (2020), 1–2
Significantly reduced both surface and airborne bacteria in critical care units by ~51% and 58%, respectively.

REDUCTION OF PARTICLES IN THE OR USING UV AIR DISINFECTION UNITS

Curtis, G.L., MD, et al. The Journal of Arthroplasty, 2017 reported the C-UVC units significantly reduce total and viable particles counts.

THE IMPACT OF SUPPLEMENTAL INTRAOPERATIVE AIR DECONTAMINATION ON THE OUTCOME OF TOTAL JOINT ARTHROPLASTY

Cook, T., DO, Piatt, C., DO, Barnes, S. BSN, Edmiston, Jr., C.E. PhD. The Journal of Arthroplasty, 2018. While PJI is multifactorial in nature, this study suggests the use of intraoperative supplemental air decontamination significantly reduced the overall risk of PJI.

THE IMPACT OF A NOVEL MAPS ON THE BACTERIAL AIR BURDEN DURING ROUTINE CARE

Werner Bischoff, MD PhD, FSHEA, Gregory Russell MS, Elisabeth Willard AAS, John Stehle Jr PhD. American Journal of Infection Control, 2019. Aerosol transmission of pathogens can result in the rapid spread of disease. The mobile air recirculation system significantly decreased the bacterial load by over 40%.

REDUCTION IN AIRBORNE BACTERIAL LEVELS USING SUPPLEMENTAL SYSTEM

W. R. Walsh, PhD, Airborne bacteria-laden particles in healthcare settings are now being recognized as a contributing cause of hospital acquired infections (HAI), and surgical site infections (SSI). OR Air Supplemental System reduced mean bacterial CFU/m³ by 57%.

DIATHERMY STUDY UTILIZING ILLUVIA 500UV

W.R. Walsh conducted a diathermy study utilizing Illuvia 500UV that found reduction in the airborne particulate count.

OUTCOME STUDY SEM OF OPERATING THEATRE AIR

W.R. Walsh, PhD., conducted a study with scanning electron microscopy to evaluate the Illuvia filtration cartridge. A significant number of airborne particulates was detected within the cartridge after each surgical procedure.

ABX OUTCOME STUDY: SSI REDUCTION RESULTS

AEROBIOTIX technology previously demonstrated statistically significant reductions in total airborne particulates, viable particulates, and airborne bacteria when deployed in active operating rooms. The study was performed in a single OR at a 300-bed community medical center in Atlanta, Georgia, USA.

ELIMINATION OF AEROSOLIZED VIRUS IN SINGLE-PASS TESTING

The Research Triangle Institute (RTI) Center for Microbial Community Systems and Health Research conducted a series of tests to determine the efficiency of viral inactivation by the Aerobiotix in–room recirculating air cleaner. MS2 virus inactivation efficiency of the Aerobiotix air cleaner was 100% observed when the unit was operated in “full on” mode.

OUTCOME STUDY SEM OF OPERATING THEATRE AIR

W.R. Walsh, PhD., conducted a study with scanning electron microscopy to evaluate the Illuvia filtration cartridge. A significant number of airborne particulates was detected within the cartridge after each surgical procedure.

MITIGATION OF AIRBORNE CARDIAC HEATER-COOLER EMISSIONS USING THE HUAIRS

Carrico, R.M. PhD DNP FSHEA CIC, Warye, K. The HUAIRS system represents a potential solution for the mitigation of bioaerosol emissions in order to eliminate SSI risk due to HCU in cardiac ORs.

Effect of portable negative pressure units on expelled aerosols in the operating room environment

Marko Popovic, Jonathan Beathe, Ejiro Gbaje, Marla Sharp, Stavros G Memtsoudis. With the portable negative pressure unit 10 cm and 30 cm from the site of aerosol emittance, the median concentration compared with background concentration was −0.5 (−8,8) particles/ft 3/min and 398 (89, 1749) particles/ft 3/min, respectively.

General Research

THE CASE FOR IMPLEMENTATION OF OPERATING ROOM AIR DECONTAMINATION TECHNOLOGY FOR ORTHOPEDIC SURGERY

Russell Nassof, JD; Kathy Warye, Maureen Spencer, MEd, RN, CIC, FAPIC. Infection Control Today, September 2018. While there is a host of factors in OR environment and practice that can contribute to SSI, there is a growing body of evidence which suggests that air quality merits heightened attention on the part of the infection prevention community.

INACTIVATION OF VIRUS-CONTAINING AEROSOLS BY ULTRAVIOLET GERMICIDAL IRRADIATION

Chun-Chief Tseng and Chih-Shan Li, National Taiwan University, Aerosol Science and Technology, 2005.
Study: to evaluate the application of UVGI for the inactivation of viruses. Conclusion: UVGI was an effective method for inactivation of airborne virus.

APIC Cost Calculator

Calculate the impact of your facility’s HAIs.

These tools incorporate your data to demonstrate the effect of healthcare-associated infections (HAIs) on mortality, deferred admissions, cost, and reimbursement.

Download GermZone Pro Specs

Download GermZone Pro Specs 📞 +1-888-978-7087

Download AeroCure 200 Specs

Download AeroCure Vac Specs

Download Illuvia®Sense Specs

Download AeroCure 200 Specs 📞 +1-888-978-7087

Download AeroCure Vac Specs 📞 +1-888-978-7087

Download Illuvia®Sense Specs 📞 +1-888-978-7087

JASON-TODD-VP-SALES-AEROBIOTIX

JASON TODD

Sr. Vice President of Global Sales and Marketing

Jason leads our global sales team and brings over 18 years of Medical Device experience to Aerobiotix. Jason has led top performing National and Regional Sales teams, selling disruptive technology in the Cardiovascular space with Getinge, Surgical Robotics at Hansen Medical and most recently in the Biologics space with Axogen. Jason received his Bachelor of Science Degree from the University of Indianapolis.

MELISSA-GIETZEN-VP-GLOBAL-MARKETING-AEROBIOTIX

MELISSA GIETZEN, MBA

Vice President of Global Marketing

Melissa Gietzen, MBA is a highly skilled strategic marketing professional with over 20 years’ experience in the healthcare industry. She has significant expertise in strategic planning, capital budgeting, service improvement projects, and creating strong successful brands in the orthopedic, cardiac & ophthalmology markets. Melissa holds a undergraduate degree in Management and Organization Development and a masters degree in Business Administration.

DAVID KIRSCHMAN, M.D. President and CEO

DAVID KIRSCHMAN, M.D.

President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.

GREGORY CARROLL PH.D. Director Scientific Affairs

GREGORY CARROLL PH.D.

Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.

TONY EMBREE Chief Commercial Officer

TONY EMBREE

Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.

COURTNEY ADAMS, Ph.D. VP of Clinical and Medical Affairs

COURTNEY ADAMS, Ph.D.

VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.

ANTHONY DEFALCO Vice President of Engineering

ANTHONY DEFALCO

Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.

NATHAN UTZ Vice President of Client Services

NATHAN UTZ

Vice President of Strategic Accounts

Nathan brings a high level of commitment to servicing and building client relations. Nathan has previously held leadership roles in the medical device industry.

MICHAEL SCHMITZ Chief Financial Officer

MICHAEL SCHMITZ

Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.